Maternal transmission of Alzheimer&apos;s disease: prodromal metabolic phenotype and the search for genes. by Mosconi, L. et al.
Maternal transmission of Alzheimer’s disease: Prodromal
metabolic phenotype and the search for genes
Lisa Mosconi1,*, Valentina Berti2, Russell H. Swerdlow3, Alberto Pupi2, Ranjan Duara4,
and Mony de Leon1,5
1Center for Brain Health, New York University School of Medicine, New York, NY 10016, USA
2Nuclear Medicine Unit, University of Florence, Careggi Hospital, 50134 Florence, Italy
3Landon Center on Aging, MS2012, Kansas City, KS 66160-7401, USA
4Wien Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center, Miami
Beach, and Miller School of Medicine, University of Miami, Miami, FL 33140, USA
5Nathan Kline Institute, Orangeburg, NY 1096, USA
Abstract
After advanced age, having a parent affected with Alzheimer’s disease (AD) is the most
significant risk factor for developing AD among cognitively normal (NL) individuals. Although
rare genetic mutations have been identified among the early-onset forms of familial AD (EOFAD),
the genetics of the more common forms of late-onset AD (LOAD) remain elusive. While some
LOAD cases appear to be sporadic in nature, genetically mediated risk is evident from the familial
aggregation of many LOAD cases. The patterns of transmission and biological mechanisms
through which a family history of LOAD confers risk to the offspring are not known. Brain
imaging studies using 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG
PET) have shown that NL individuals with a maternal history of LOAD, but not with a paternal
family history, express a phenotype characterised by a pattern of progressive reductions of brain
glucose metabolism, similar to that in AD patients. As maternally inherited AD may be associated
with as many as 20 per cent of the total LOAD population, understanding the causes and
mechanisms of expression of this form of AD is of great relevance. This paper reviews known
genetic mutations implicated in EOFAD and their effects on brain chemistry, structure and
function; epidemiology and clinical research findings in LOAD, including in vivo imaging
findings showing selective patterns of hypometabolism in maternally inherited AD; possible
genetic mechanisms involved in maternal transmission of AD, including chromosome X
mutations, mitochondrial DNA and imprinting; and genetic mechanisms involved in other
neurological disorders with known or suspected maternal inheritance. The review concludes with a
discussion of the potential role of brain imaging for identifying endophenotypes in NL individuals
at risk for AD, and for directing investigation of potential susceptibility genes for AD.
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Alzheimer’s disease: Incidence and clinical profile
Alzheimer’s disease (AD) is the most common form of dementia in late life, affecting
approximately 10 per cent of individuals of 65 years of age, with the prevalence doubling
every five years up to the age of 80, above which the prevalence is 40 per cent.1 In 2008, in
the United States alone, there were more than 5 million people with AD, which is a 10 per
cent increase from the previous (in 2000) prevalence estimate of 4.5 million (Figure 1,
adapted from Hebert et al.2). Age-related mild cognitive impairments may affect two to
three times as many individuals.3,4 By 2050, the number of elderly people with AD in the
USA could range from 11 million to 16 million, which strongly calls for strategies to
prevent or delay the onset of the disease.
AD is a neurodegenerative disorder characterised by global deficits in cognition, ranging
from memory loss to impaired judgment and reasoning.5 Clinical diagnosis per se is often
uncertain and clinical assessment requires multiple examinations and laboratory tests over
time. Despite thorough clinical exams, the frequency of unrecognised dementia in the
community ranges from 50 per cent to 90 per cent of cases.6 Insidious onset and progressive
impairment of memory and other cognitive functions make the initial stages of AD difficult
to distinguish from so called ‘normal ageing’. In order to develop prevention treatments for
AD, it is necessary to identify persons who are still cognitively normal (NL), but are either
at very high risk for developing the disease or are in an early, pre-symptomatic stage of the
disease. Such individuals are most likely to benefit from therapies which are instituted when
the potential for preservation of function is the greatest, well before irreversible synaptic and
neuronal injury.
The difficulty in studying the genetics of complex, age-associated disorders such as late
onset AD (LOAD) using traditional clinical case identification measures has resulted in an
increasing emphasis on studying endophenotypes of AD, which provide more specific
targets for genetic studies. In 2007, it was shown that NL children of mothers affected with
LOAD express a biological phenotype characterised by progressive reductions in brain
glucose metabolism in the same brain regions as clinical AD patients, as measured on 2-
[18F]fluoro-2-deoxy–D–glucose positron emission tomography (18F-FDG PET).7 By
contrast, children of AD-affected fathers and of parents with no dementia did not show
metabolic abnormalities.7 The genetic basis for the selective maternal transmission of
metabolic deficits in AD is not known.
The present review first summarises known genetic mechanisms involved in the early- and
late-onset forms of AD, and in vivo brain imaging studies that provide a link between
genetics, pathology and pathophysiology in AD. It then presents recent findings of
progressive reductions in brain glucose metabolism in adult children of mothers affected
with LOAD, and discusses possible genetic and epigenetic mechanisms involved in
maternally inherited brain hypometabolism. Finally, it examines other neurological disorders
with known or suspected maternal transmission, and discusses the role of imaging in
identifying endophenotypes in preclinical AD.
Although many imaging methods are available, this review will focus on the two most
widely utilised brain imaging techniques in both clinical practice and research studies in AD
— magnetic resonance imaging (MRI) and PET. Various MRI and PET studies in AD have
been published recently.8-13 Briefly, these methods have long been used in AD for the
detection of structural brain changes and volume reductions due to neuronal loss (ie atrophy)
on MRI, and reductions of cerebral metabolic rate of glucose (CMRglc) on 18F-FDG-PET.
Both modalities accurately discriminate AD from controls, predict decline from normal
cognition to dementia and correlate with disease progression and histopathological
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diagnosis.8-13 In addition, 18F-FDG-PET has the advantage of being particularly useful for
distinguishing AD from other forms of dementia.10-13 Overall, AD patients present with
brain atrophy and hypometabolism in the parieto-temporal, posterior cingulate, medial
temporal and prefrontal cortex, while the primary motor and visual areas, cerebellum,
thalamus and basal ganglia are relatively spared.8-13
In addition to traditional imaging techniques, a turning point in AD was accomplished with
the recent development of PET tracers for amyloidbeta (Aβ) plaques, which allow
examination of Aβ deposits in vivo. Among different amyloid PET ligands, the best
characterised is the N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole, also
known as Pittsburgh compound-B (11C-PIB).14 AD patients consistently show 11C-PIB
uptake in amyloid-rich brain regions, particularly in the frontal, parieto-temporal, posterior
cingulate, precuneus and occipital cortices, as well as the thalamus and striatum, whereas the
control population mostly showed non-specific binding restricted to the white matter.
8,15,16-18 A combination of imaging modalities may help to make an earlier diagnosis, and
to define the nature and extent of AD pathology among pre-symptomatic individuals.
Autosomal dominant genetic transmission of AD: The early-onset forms
The three genes that are causative of AD
A central role for Aβ in AD is strongly supported by studies of the rare early-onset (<60
years) forms of familial AD (EOFAD). Genetic factors that have been firmly implicated in
EOFAD are mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and
presenilin 2 (PSEN2) genes, which are found in large multi-generational families with an
autosomal dominant pattern of disease inheritance. Major findings from studies of EOFAD
mutation carriers are summarised in Table 1.
In 1990, the first mutation in the gene encoding APP, on chromosome 21, was discovered in
a pedigree with Dutch-type hereditary cerebral haemorrhage with amyloidosis. Shortly after,
a missense mutation occurring in the same APP exon (exon 17) was detected in patients with
EOFAD.19,20 Although APP mutations account for less than 0.1 per cent of all AD cases,
they have virtually complete penetrance.19,20 Only a year later, a second EOFAD locus was
linked to chromosome 14, and the gene was later identified as PSEN1.20 PSEN1 is fully
penetrant, has an age of onset of disease between 28 and 65 years and is responsible for the
majority of EOFAD mutations identified thus far. A second presenilin gene (PSEN2), on
chromosome 1, is responsible for six other EOFAD mutations. On average, EOFAD
mutations in PSEN2 exhibit a later age of onset of disease (ranging from 43 to 80 years) than
those in APP or PSEN1.19,20
The pathophysiology associated with EOFAD genes
Studies of the effects of these genetic mutations suggested a central role for Aβ in the
pathogenesis of AD. Definitive diagnosis of AD requires postmortem observation of specific
pathological lesions: Aβ plaques, neurofibrillary tangles (NFT) containing
hyperphosphorylated tau protein, synaptic loss and brain atrophy in specific brain areas.21,22
EOFAD mutations in the APP and PSEN genes generally shift the processing of APP to
Aβ42, leading to an increased ratio of Aβ42 to Aβ40 (Table 1).20 At post-mortem, EOFAD
cases consistently show substantial AD pathology — particularly diffuse and numerous Aβ
plaques surrounded by activated microglia — associated with extensive synaptic loss and
brain atrophy.20 Aβ peptides are formed from APP and cluster into amyloid plaques on the
blood vessels and in the extraneuronal space.23,24 Aβ peptides are toxic to cell cultures.25,26
Ageing appears to render the brain more vulnerable to Aβ toxicity,27 and Aβ further impairs
mitochondrial function in ageing brains and initiates a neurotoxic cascade with parallel
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overproduction of free radicals.28 In AD, Aβ pathology was shown to occur upstream of tau
pathology, and recent studies have shown that Aβ may lead to NFT formation within cells.29
Nonetheless, a causal relationship between Aβ and tau pathology in AD remains to be
clarified.
Clinically, EOFAD is characterised by a specific age of onset of cognitive impairment for a
given pedigree. Therefore, studies of pre-symptomatic mutation carriers close to the
expected age of onset provide unique information about preclinical AD-related brain
changes. Asymptomatic and symptomatic PSEN1 mutation carriers showed significant
reductions in brain tissue (ie atrophy) on MRI and in global CMRglc on FDG-PET, as
compared with age-matched controls.30 CMRglc reductions on FDG-PET were shown to
exceed MRI volume loss in pre-symptomatic PSEN1 carriers.31
Amyloid imaging with 11C-PIB PET showed higher amyloid load in both asymptomatic and
symptomatic individuals carrying PSEN1 mutations compared with controls.32 11C-PIB
retention was especially high in the striatum of all PSEN1 mutation carriers compared with
controls and sporadic AD patients. Symptomatic mutation carriers showed significant tracer
retention also in the cortical regions, although uptake was not as high as in sporadic AD
subjects.32 These findings suggest that amyloid deposition in PSEN1 mutation carriers may
begin in the striatum before the onset of symptoms, and later spread to neocortical regions.
32,33 The data may also point to different patterns of Aβ deposition in AD, however, with
the striatum being more affected in EOFAD and the cortex being more affected in the late-
onset forms. A similar pattern of prominent 11C-PIB retention in the striatum, especially in
the caudate nucleus and putamen, was also found in EOFAD patients with APP mutations.34
APP recessive mutations
While most studies demonstrated an association between autosomal dominant APP
mutations and EOFAD forms, a recent study identified a mutation in the APP gene (A673V)
that causes AD only in the homozygous state, reflecting recessive Mendelian inheritance.35
Affected carriers presented at 36 years of age with behavioural changes and cognitive
deficits, leading to severe dementia, spastic tetraparesis and a complete loss of autonomy.35
This APP mutation was shown in vitro to have two pathogenic effects: shifting of APP
processing toward the amyloidogenic pathway and enhancement of the aggregation of
fibrillogenic Aβ.35 Among heterozygotes, the interaction between wild-type and mutant Aβ
produced by the non-mutated and mutated alleles appeared to hinder amyloidogenesis and
neurotoxicity, thus protecting heterozygous carriers from developing the clinical syndrome.
Another homozygous APP mutation (A693D) resulted in clinical AD among three AD
patients from a Japanese pedigree.36 A heterozygous member of the same family was found
to have mild cognitive impairment (MCI), which may lead to AD.36 It remains to be
established whether A693D is a recessive mutation or a dominant APP variant with
incomplete penetrance.
LOAD and the role of risk-modifying genes
The lesson learned from studying APP and PSEN mutations is that Aβ dysmetabolism may
be a primary event in the pathogenesis of EOFAD. Whether this mechanism of action of Aβ
leads to the more common, late-onset forms of AD remains to be determined. While the rare
EOFAD cases have autosomal dominant inheritance and the onset and progression of the
disease appears relatively independent of non-genetic factors, LOAD, which comprises 99
per cent of the AD population after the age of 60, does not seem to be associated with
clearly discernible nuclear genetic mutations. Several genetic and non-genetic factors
influence the risk for the development of LOAD and modify both the age at onset and the
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course of the disease. These include genes (predisposing risk alleles), sociodemographic
background (education, intellectual engagement), lifestyle (diet, fitness), environment and
medical history (head trauma, medications, smoking, vascular diseases, etc).
Studies of monozygotic (MZ) and dizygotic (DZ) twins affected by LOAD suggest that
genetic influence may predominate over environmental influence.37,38 In a twin study, a
twin pair can either be concordant (both individuals have the disorder) or discordant (only
one of two is affected). MZ twins share all of their chromosomes, while DZ twins do not.
Therefore, evidence that MZ twins are more concordant for AD than DZ twins would
indicate stronger genetic influence. Evidence for the role of the environment comes from
MZ twins who are discordant for the disease. Results from Swedish and Finnish twin
registries have shown high rates of concordance for AD (over 80 per cent for MZ and 46 per
cent for DZ) and high heritability (≥74 per cent).38,39 Genetic influence on the age of onset
of AD is demonstrated by the fact that it was more concordant for MZ compared with DZ
twin pairs.38
The challenge in identifying genetic factors involved in LOAD may be due to a combination
of variables, which include its insidious onset and slow progression, the complexity of most
age-related conditions, the variable influence of various environmental and medical
conditions often over a period of decades and the lack of sensitive and specific criteria for
incipient AD. Because it is necessary for other family members to survive until the age of
onset of the disease, cases may not be recognised as being familial. Genetic association
studies in LOAD have identified single DNA sequence variations within a single nucleotide
—that is, single nucleotide polymorphisms (SNPs; these are DNA sequence variations that
occur when a single nucleotide [A, T, C or G] in the genome sequence is altered) or
haplotypes (ie a combination of alleles at multiple loci that are transmitted together on the
same chromosome, or can be defined as a set of SNPs on a single chromosome that are
statistically associated)—that are associated with increased risk. Although several SNPs
within specific genes have been reported to be associated with LOAD, this review will focus
on more widely studied polymorphisms in five genes: apolipoprotein E (ApoE), sortilin-
related receptor 1 (SORL1), growth factor receptor bound (GRB)-associated binding protein
2 (GAB2), protocadherin 11 (PCDH11X) and kidney and brain (KIBRA) genes. Major
findings from studies of susceptibility genes involved with LOAD are summarised in Table
1.
ApoE
In 1993, Strittmatter and colleagues discovered that carriers of the epsilon 4 (ε4) allele of the
gene encoding ApoE, located on chromosome 19, are at higher risk for AD than non-
carriers.40 ApoE contains two SNPs that result in three possible alleles for this gene: ε2, ε3
and ε4. Each allele differs by one DNA base, and the protein product of each gene differs by
one amino acid. Case-control studies showed that the ApoE ε4 genotype occurs in
approximately 40 per cent of all LOAD patients and is also over-represented in EOFAD.19
Animal and human studies suggest that the association of the ApoE ε4 allele with AD is
mediated primarily by a dose-dependent effect of the ε4 allele on the deposition of Aβ in the
brain.41-45 Some have speculated that ApoE may also influence AD risk by disrupting
microtubule-associated tau protein metabolism.19,46
MRI studies have demonstrated an association between the ε4 allele and hippocampal
atrophy, with the rate of hippocampal volume loss being greater for the ε4 carriers than for
the non-carriers.47,48 18F-FDG PET studies showed that, compared with non-carriers,
asymptomatic carriers of the ApoE ε4 genotype show CMRglc reductions within the brain
regions typically affected in clinical AD patients.49 They also showed greater CMRglc
declines over time.49 Despite its well-established association with AD, the ApoE ε4
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genotype has no clear familial pattern of transmission and appears to act as a risk modifier
by lowering the age at onset of clinical symptoms, rather than as a causal determinant.
19,50-52.
SORL1
Recent studies have shown an association between SORL1, located on chromosome 11, and
LOAD. Genetic changes in SORL1 expression appear to be causally linked to the
pathogenesis of AD and to increased risk for the disease.53 In particular, SNPs in different
regions of SORL1 were associated with AD in multiple ethnically diverse samples53-55 and
also in the Translational Genomics Research Institute (TGEN) database.56 Evidence for
various AD-associated haplotypes supports the notion that there may be a high degree of
allelic heterogeneity, with disease-associated variants occurring on multiple different
haplotypic backgrounds.
SORL1 encodes a protein that modulates subcellular trafficking of APP.53 Reduced
expression of SORL1 leads to release of APP into endosomal pathways, where it is subjected
to beta- and gamma-secretase cleavage, with subsequent production of Aβ. The SORL1
protein also belongs to a superfamily of low-density lipoprotein receptors (SorLA/LR11)
which bind ApoE and are implicated in cholesterol metabolism and atherogenesis. There is
evidence for reduced SORL1 expression in the brains of patients with AD,57 which was
found to be associated with increased Aβ production.58 In AD patients, SORL1 variants
associated with AD are also associated with whole-brain and hippocampal atrophy on MRI.
59 Heterogeneity still remains in SORL1 alleles, however, and broad regions of SORL1 still
need to be examined for functional pathogenic variants.
GAB2
GAB2, on chromosome 11q, was recently identified as a susceptibility gene for LOAD.60 A
genome-wide association study reported that a haplotype encompassing six polymorphisms
of the GAB2 gene is associated with a higher risk of developing AD,60,61 especially in ApoE
ε4 allele carriers.61 The hypofunctional GAB2 haplotype is thought to be associated with a
reduced GAB2-protective effect on neurones. GAB2 is a scaffolding protein involved in
multiple signalling pathways, which is thought to protect cells from NFT formation and cell
death.62 Neuronal microarray studies provided evidence that GAB2 is biologically relevant
to AD neuropathology by showing that LOAD cases had significantly greater neuronal
GAB2 expression in the posterior cingulate cortex and hippocampus than controls.60 The
relationship between GAB2 polymorphisms and Aβ metabolism has not yet been
established.
PCDH11X
PCDH11X is a gene located on chromosome X encoding protocadherin 11. Protocadherin
belongs to the cadherin family of cell surface receptor molecules. The cadherin proteins
mediate cell–cell adhesion and have a role in cell signalling that is critical in the
development of the central nervous system. Notably, some protocadherins are known to
undergo presenilin-dependent processing.63 A genome-wide association study identified a
SNP on chromosome X which resides in a haplotype block that falls entirely within
PCDH11X and strongly segregated with LOAD.64 Female homozygotes showed a
significantly increased risk for AD compared with female non-carriers, female heterozygotes
and male hemizygotes.64 Moreover, female heterozygotes were at increased risk over female
non-carriers, and male hemizygotes were at higher risk than male non-carriers.64 To obtain a
perspective about the importance of PCDHX11 to LOAD, it is useful to compare the risk for
LOAD associated with PCDHX11 with that for ApoE. The odds ratio for LOAD associated
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with the homozygous ApoE ε4 allele is 11.5, whereas for homozygous PCDH11X it is 1.75
(http://www.physorg.com/news150905504.html). These results await replication.
KIBRA alleles
Recent genome-wide studies aimed at identifying memory-related gene variants have shown
an association between the KIBRA gene on chromosome 5q and human memory
performance.65,66 KIBRA is a cytoplasmic protein that is highly expressed in the brain and
is a binding partner of dendrin, a putative modulator of synaptic plasticity. A SNP within the
ninth intron of KIBRA was shown to influence episodic memory.65 There are two allelic
variants of KIBRA (T and C), which result in three possible genotypes: TT, CT and CC.
KIBRA T allele carriers (CT and TT genotypes) had better episodic memory performance
than KIBRA CC carriers in young, middle-aged and elderly subjects.65,66 Moreover, KIBRA
CC carriers had a moderate but significantly increased risk of AD compared with TT and CT
carriers.67,68
In functional MRI (fMRI) studies, KIBRA CC carriers showed greater activation of the
hippocampus and frontal and parietal cortex compared with the T allele carriers during an
episodic memory task, suggesting that these memory retrieval-related regions had to work
harder to perform the task in the T allele non-carriers.65,67 Moreover, 18F-FDG PET studies
showed that cognitively normal KIBRA CC carriers had significantly lower CMRglc than
KIBRA TT and CT carriers in the posterior cingulate cortex.67
Although familial LOAD shows high heritability, which indicates genetic involvement, no
well-replicated susceptibility genes have been identified to date, with the exception of ApoE
and SORL1. Studies are mostly hindered by the fact that LOAD is a common complex
disorder of old age, with multi-factorial causes, including genetic and environmental
components. Such aetiological complexity makes identification of LOAD-related genes
challenging, whereas an ‘endophenotype approach’ may afford some advantage.69
Measuring phenotypic variation in pre-selected, homogeneous populations may expedite the
search for specific genotypes.
Family history of LOAD: Evidence for maternal transmission
Prevalence and risk
Descriptively, two main variants of LOAD can be identified:
1. LOAD with a familial component (LOFAD), which includes:
• Individuals with a parent, or both parents, affected with AD
• Individuals with first-degree family members other than the parents
affected with AD (ie siblings)
• Individuals with second-degree family members affected with AD (ie
aunts, uncles, grandparents)
• Combinations of the above.
2. LOAD that appear to be sporadic in nature (LOSAD). These individuals are the
first in their families to develop AD.
After advanced age, having a first-degree family history of LOAD is the most significant
risk factor for developing AD among NL individuals.70,71 First-degree relatives of affected
probands have a four- to tenfold higher risk for developing AD than the general population,
with some variability depending on which family members are affected.72-74 Children of
affected parents are at especially high risk of AD, as confirmed in multiethnic studies.73
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Although having one parent with AD is per se a major risk factor for developing AD in the
offspring, individuals with both parents affected appear to be at even greater risk for AD,
compared with those with one affected parent and with the general population.75,76 In
general, individuals with LOFAD tend to develop dementia at younger ages than in LOSAD.
77 Moreover, the age at onset of AD was lower in children with both parents with AD (mean
age of onset 57 years, range 48–66) compared with children with one parent with AD (mean
age of onset 60 years, range 50–80), and with those with no parents affected (mean age of
onset 72 years, range 48–88).75
Although there is mixed evidence for parent of origin gender effects in LOAD families,78,79
epidemiological studies have shown that maternal transmission of AD may have a greater
impact on the offspring’s health than paternal transmission. AD affects more women than
men, with a relative risk of 1.5–3.6 across different ethnic groups,73 and maternal
transmission is more frequent than paternal transmission of AD.80 In AD patients with one
affected parent, the ratio of mother-to-father affected is approximately 3:1 (Table 2). A
review of the AD literature70,77,78,80,81 and data from the authors’ current studies show that
approximately 20 per cent of all LOAD cases are maternally inherited. Importantly, having
an AD-affected mother was found to be associated with poorer cognitive performance in late
life82 and with a lower and more predictable age at onset of dementia in the offspring,
compared with having an AD-affected father.77,80,83
There are no published studies that have examined whether cognitive performance
deteriorates at younger ages in individuals with both parents affected, compared with those
with one parent with AD. As individuals with both parents with AD are relatively rare
(estimated prevalence is 3–5 per cent of the total AD population)75 their clinical profile has
been poorly studied.
At present, the absolute risk to the offspring associated with either an affected mother or
father is not known. There is a paucity of longitudinal studies in pre-symptomatic AD. It is
not known whether the prevalence of cognitive decline from normal to AD is higher in
children of AD mothers compared with children of AD fathers, or with different family
history. The genetic and pathological mechanisms through which a parental, especially
maternal, history of AD confers increased susceptibility to the offspring remain largely
unknown. Genetically mediated risk for a large proportion of LOAD cases is evident from
the familial aggregation of AD and is only partially explained by the risk conferred by ApoE
ε4 alleles. The ApoE ε4 genotype is found in fewer than 40 per cent of LOFAD cases,70 and
not everyone with an ApoE ε4 allele will develop AD. This indicates that other factors
contribute to the aetiology and phenotypic expression of the disease. Thus far, these
epidemiological and clinical findings have not been thoroughly characterised by the use of
bio-markers, and LOFAD phenotypes have not been fully studied.
Brain imaging studies of maternal history of AD
18F-FDG PET imaging studies have provided evidence for phenotypic differences between
NL individuals with a maternal history of AD and those with a paternal family history.7,84
Examination of a group of over 50 50–80-year-old clinically normal and NL individuals
showed that those subjects with an AD mother had reduced CMRglc compared with those
with an AD father and with those with no parents affected (Figure 2).7 CMRglc reductions
in the children of AD mothers involved the brain regions typically affected in clinical AD
patients — namely, the parieto-temporal, posterior cingulate/precuneus, medial temporal
and prefrontal cortices. No CMRglc differences were found between children of AD fathers
and children of parents with no dementia. Moreover, CMRglc reductions in children of AD
mothers remained significant after accounting for other possible risk factors for AD, such as
age, gender, education and ApoE genotype. Importantly, hypometabolism was found within
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the group of maternal AD subjects irrespective of their ApoE status. ApoE ε4 non-carriers
with an AD mother showed CMRglc reductions compared with the ApoE ε4 non-carriers
with an AD father and those with no parents affected. These data show that CMRglc
reductions in individuals with an AD mother occur independently of the subjects’ ApoE
genotype.7
Over a two-year follow-up interval, CMRglc reductions in NL subjects with an AD mother
were observed to be progressive.84 Longitudinally, subjects with an AD-affected mother
showed progressive, bilateral CMRglc reductions in the posterior cingulate/precuneus,
parieto-temporal and frontal cortices (Figure 3). By contrast, individuals with an AD-
affected father and those with no parental history of AD showed longitudinal CMRglc
reductions restricted to the frontal cortex, which is a typical effect of the ageing process.
Within all these brain regions, CMRglc reductions over time were more severe in children of
AD mothers compared with the other groups.84
This study included two subjects, one with an AD mother and the other with an AD father,
whose AD parents were autopsied and given a postmortem diagnosis of AD. Examination of
the individual 18F-FDG PET scans of these subjects showed that, compared with controls,
the 68-year-old NL son of an AD-affected father did not show hypometabolism in any brain
regions, whereas the 58-year-old NL daughter of an AD-affected mother showed significant
CMRglc reductions in AD-vulnerable regions (Figure 4).
Of relevance to the above results, 18F-FDG PET studies in NL elderly individuals showed
that CMRglc reductions in AD brain regions both predict and correlate with the decline from
normal cognition to MCI and AD.85,86 Reduced CMRglc at baseline accurately predicted
future cognitive decline from normal to AD with 81 per cent accuracy, and from normal to
MCI with 71 per cent accuracy.86 Over the study interval, the rate of CMRglc reduction was
four times higher in the progressors to AD, than in the non-progressors.86
The current observations suggest, and further longitudinal studies will be needed to confirm,
that NL children of AD-affected mothers who have progressive CMRglc reductions in AD
regions may be in the preclinical stages of AD. Clarification is also needed about whether an
additive effect on regional hypometabolism occurs when both parents are AD affected.
Finally, multi-modality imaging is warranted to assess the relationship between
hypometabolism in children of AD mothers with Aβ and NFT pathology, or other biological
markers of AD.
Searching for genes involved in maternally inherited AD
Classical genetic studies are challenging to perform in LOAD cases because the parents are
usually not alive or the children are too young to manifest the phenotype of the disease. The
above brain imaging findings in children of AD mothers provide a unique opportunity for
studying and uncovering new genetically mediated risk factors for LOAD. Although
Mendelian inheritance is not evident in LOFAD, the fact that children of affected
individuals have an increased risk of developing the disease suggests a genetic component.
Moreover, the fact that only children of affected mothers show CMRglc reductions
consistent with AD, suggests a maternally inherited predisposition to brain ‘energetic’
failure. The most likely genetic mechanisms to explain maternally inherited AD would
appear to be (in alphabetical order):
• chromosome X-mediated transmission
• epigenetic imprinting
• mitochondrial DNA-mediated transmission
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• sex-specific trinucleotide repeat expansions-mediated transmission,
Chromosome X
Chromosome X-linked diseases are disorders that reflect the presence of defective genes on
the X chromosome. The vast majority of X-linked diseases are characterised by recessive
transmission with the following features: 1) males are more frequently affected than females
because they are hemizygous and the gene defect is not balanced by a normal X
chromosome; 2) females are rarely affected because they need to be homozygous for the
defective gene to manifest the phenotype; 3) there is no male-to-male transmission; 4)
transmission of the defective gene occurs from fathers to daughters, who become carriers; 5)
males born to a carrier mother have a 50 per cent probability of inheriting the X
chromosome carrying the defective gene. Classical examples of X-linked transmission are
red–green colour blindness and haemophilia A.
The presence of X-linked inheritance could be a possible explanation for the higher
prevalence of maternal transmission of AD. As described above, the ‘X-linked hypothesis’
for a LOAD gene was supported by a recent genome-wide association study, which
identified a strong association between LOAD and a mutation located on the PCDH11X
gene on chromosome X.64 Female homozygotes were at significantly increased risk for AD
compared with female non-carriers, female heterozygotes and male hemizygotes.64
Moreover, female heterozygotes were at greater risk than female non-carriers, and male
hemizygotes were at higher risk than male non-carriers.64
Although maternally inherited LOFAD and X-linked diseases may share some
characteristics, several properties of recessive X-linked disorders do not apply to LOFAD.
First, PCDH11X mutations were associated with higher risk in female homozygotes than
male hemizygotes, which is contrary to what is usually found in X-linked recessive
disorders.64 Secondly, there is no male-to-male transmission in X-linked inheritance,
whereas father-to-son transmission has been reported in AD.79,80 Although limited by
sample size, in the authors’ PET studies, there was no evidence for gender effects in the
offspring of AD mothers.7 Males withanADmother did not show more severe
hypometabolism when compared with females with AD mothers. These results need to be
confirmed with larger data sets specifically to examine the interaction between family
history and gender on brain metabolism and other variables.
Genomic imprinting
Genomic imprinting is a genetic process by which certain genes are expressed in a parent-
of-originspecific manner, which does not follow classical Mendelian inheritance.87 While
expression of the majority of genes derives from both inherited copies (alleles) of the gene, a
small proportion (<1 per cent) of genes are imprinted, which means that gene expression
occurs from only one allele. In the majority of cases, one of the parental alleles is
completely silenced and gene expression is monoallelic. This silencing mechanism is known
to involve epigenetic marking by allele-specific DNA methylation and/or histone
modifications.88 Differential epigenetic marking of the parental chromosomes results in
differential reading by the transcriptional machinery and, as a consequence, gene expression
is predominantly from one parental allele. For example, the gene encoding insulin-like
growth factor 2 (IGF2/Igf2) is only expressed from the allele inherited from the father.
For a gene that is normally imprinted with paternal silencing, a mutation in the maternal
copy of the gene will result in disease, while a mutation in the paternal copy will have no
effect, and vice versa. According to the parental conflict hypothesis, paternal imprinting
appears to be growth promoting, while maternal imprinting would be growth limiting.89
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More specifically, the paternal genome maximises extraction of maternal resources for the
benefit of the paternal offspring, at the expense of offspring from other embryos, possibly
from different fathers. By contrast, the maternal genome limits nutrient provision to each
individual embryo to distribute resources equally among her offspring, independent of the
fathers. Irrespective of parental origin, the majority of imprinted genes in mammals have
roles in the control of embryonic growth and development, including development of the
placenta, and in postnatal development, with roles affecting suckling and metabolism.87
Imprinted genes are susceptibility targets for numerous human pathologies because their
functional haploid state enables a single genomic or epigenomic change to dysregulate their
function. Recent evidence has highlighted the role of genetic imprinting on brain function
for PraderWilli and Angelman syndromes, as well as more common disorders like diabetes,
obesity, breast cancer, autism, bipolar disorder, Tourette’s syndrome, epilepsy and even AD.
87 Maternal imprinting may be a genetic mechanism responsible for the increased maternal
inheritance in LOFAD cases. Some reports showed that the methylation process involved in
imprinting is altered in AD patients, compared with controls.90 A genome-wide screening of
AD families reported a linkage between LOAD and a region close to the centromere of
chromosome 10q only in families with an AD affected mother.91 While these findings
suggest imprinting,91 there is no clear evidence for the existence of imprinted genes in AD
families on chromosome 10 or on other chromosomes.
With respect to our 18F-FDG PET findings, hypometabolism in children of AD mothers
suggests ‘metabolic imprinting’. Metabolic imprinting refers to the epigenetic programming
of metabolism during the prenatal and neonatal periods and may have long-term
consequences for health.87 For example, glucocorticoid exposure in late pregnancy and
foetal under-nutrition have been linked to increased risk for cardiovascular disease, obesity,
type two diabetes and hypertension.87,92 In animal studies, most of the 80 known imprinted
genes are expressed in the placenta and influence maternofoetal nutrient transfer during
gestation and placental growth.93 Maternal nutrition itself was shown to have a role in
hormonal imprinting. The presence of harmful substances or the lack of important substrates
in the mother’s diet can induce adult-onset disease in the progeny.92 Little is known about
hormonal imprinting of the brain, however, and there are currently no studies that have
examined imprinting as a source of metabolic dysregulation in AD.
Finally, there is evidence from animal models for X chromosome-linked imprinted genes
that could influence sexually dimorphic neurobiology.94 The X chromosome is enriched for
genes affecting neurodevelopment. Investigations into imprinted genes on chromosome X
may provide insights into why women and men apparently show differential vulnerability to
AD.94 As with chromosome X mutations, findings of gender effects on brain deficits would
support a role for this mechanism in AD.
Mitochondrial DNA
Mitochondrial disorders are entirely maternally inherited in humans and are characterised by
variable phenotypic expression. Male and female progeny are equally likely to receive
mutant maternal mitochondrial DNA (mtDNA). The same mtDNA mutation may affect
different organs in different individuals, and may lead to minor or severe defects. The
prominent role of mitochondrial function in regulating molecular processes involved in
glucose metabolism suggests the possibility that mtDNA mutations, with resulting
mitochondrial dysfunction and oxidative damage, may be involved in the pathophysiology
of AD. Mitochondrial dysfunction may also be responsible for alterations in glucose
metabolism in AD brain tissue95 and the selective metabolic impairment in children of AD
mothers. The fact that mtDNA is exclusively maternally inherited in humans lends support
to this hypothesis.
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Human mtDNA is a 16,569-kilobase circular, double-stranded molecule, which contains 37
genes: two rRNA genes, 22 tRNA genes and 13 structural genes that encode electron
transport chain (ETC) subunits and the mitochondrial ATP synthase. While most ETC
proteins (ie complex II, coenzyme Q and cytochrome c) are encoded by nuclear DNA,
mtDNA encodes the catalytic components of complexes I, III, IV and V, all of which are
essential for maintaining physiological oxidative phosphorylation (OXPHOS). OXPHOS is
the process that accounts for the high ATP yield by the cells, and is essential to the
maintenance of cellular homeostasis and function.
The brain has high energy requirements, contains a large number of mitochondria and is
therefore highly susceptible to reductions in aerobic metabolism. Deficient energy
metabolism may change the overall oxidative microenvironment for neurones during the
pathogenesis of AD, rendering synapses more vulnerable to Aβ and tau pathology.
Mutations of mtDNA lead to a number of illnesses caused by inadequate energy supply that
mostly present as neuromuscular diseases.96 These range from exercise intolerance to
diseases with severe body-wide impact, such as the mitochondrial encephalopathy, lactic
acidosis and stroke syndrome (MELAS — a rare form of dementia associated with seizures);
headaches; muscle disease and stroke-induced paralysis; and Kearns–Sayre syndrome
(KSS), which causes a person to lose full function of their heart, eye and muscle
movements. In addition to mitochondrial myopathies, other mtDNA diseases include
diabetes mellitus and deafness (DAD), Leber’s hereditary optic neuropathy (LHON) and
Leigh syndrome (see below).
For more than 15 years, evidence has accumulated that AD is associated with mitochondrial
dysfunction, oxidative stress and increased reactive oxygen species (ROS) production. At
postmortem, extensive oxidative stress is found in AD brains, in which basically all cellular
macromolecules (protein, DNA, lipids) are found in an oxidised form.97-99 A specific
mitochondrial defect demonstrated in AD is reduced cytochrome oxidase (COX) activity in
brain regions showing neuronal loss.100-104 COX (ETC complex IV) is the mitochondrial
enzyme responsible for the activation of oxygen for aerobic energy metabolism and is
critically tied to ATP production in mitochondria.105,106 COX is localised primarily in
mitochondria near excitatory synapses in neuronal dendrites, and its activity is tightly linked
to the regulation of CMRglc in the synapses.105 Preferentially reduced COX activity in AD
was shown in several in vivo studies of blood platelets107-112 and fibroblasts.100,111,113
Platelet mitochondria COX activity was also significantly reduced in MCI patients
compared with controls.112 Overall, these studies provide evidence for peripheral
abnormalities in COX activity and increased oxidative stress in such cells as blood platelets
and fibroblasts, which are non-degenerating tissues and should not be affected by brain
pathology. This suggests that COX reductions may not be simply a secondary or
epiphenomenal consequence of neurodegeneration, but may instead represent a systemic
perturbation in AD.
Nonetheless, mtDNA studies in AD have provided non-conclusive, and often conflicting,
results. Studies that investigated the role of mtDNA mutations in AD have used three main
approaches: cytoplasmic hybrid (cybrid) analyses, case-control mutation identification
studies and mitochondrial haplogroup association studies. Studies of cybrid cells provide
direct evidence for mtDNA involvement in the metabolic abnormalities characteristic of AD
(Figure 5). Cybrids are obtained by mixing mtDNA from affected patients’ platelets with
cell lines depleted of their own endogenous mtDNA, resulting in cell lines containing
mtDNA from the patient.115 These cell lines expand under standard culture conditions, and
their biochemical assessment allows investigators to evaluate parameters directly or
indirectly referable to mitochondria and presumably the mtDNA they carry.116 Cybrid data
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in AD show that mtDNA at least partly accounts for impaired metabolism and increased
oxidative stress in AD, as reflected in increased ROS production. Defects in mitochondrial
respiratory enzymes, particularly affecting COX activity, increase changes in calcium
homeostasis, decrease ATP production, enhance Aβ toxicity and vastly increase the
percentage of morphologically abnormal mitochondria.117-120
In addition to cybrid studies, several case-control studies using mutation identification and
mitochondrial haplogroup association studies suggest that maternally inherited mutations of
mtDNA may play a pathogenic role in AD (Table 3). Despite the observation of mtDNA
mutations in AD versus controls, and of associations observed between specific haplotypes
and an increased risk for AD, however, many of these exploratory findings were not
confirmed by subsequent studies.95 Therefore, the role of mitochondrial genome changes in
the pathogenesis of ageing and AD needs further clarification, and it is possible that the
maternally inherited metabolic endophenotype may be helpful for such investigations.
Sex–specific trinucleotide repeat expansions
Trinucleotide repeat disorders (TRD) are a class of molecular diseases characterised by the
presence of unstable and abnormal expansions of DNA triplets (trinucleotides). Mutations
present as a subset of unstable repeats that occur throughout the genomic sequence, resulting
in chromosomal instability. Generally, the larger the expansions, the more likely they are to
cause disease or increase the severity of disease. This property results in the phenomenon of
genetic anticipation, as is evident in TRDs, in which there is a tendency for age of onset to
decrease and severity of symptoms to increase through successive generations of an affected
family, due to the expansion of these repeats.130 Large increases or expansions in the
number of trinucleotide tandem repeats are involved in a number of inherited
neurodegenerative conditions, which appear to be specific to the gender of the transmitting
parent. For example, in Huntington’s disease there is an increased number of CAG repeats,
and this condition is preferentially paternally inherited.131 Some neurological TRDs show a
preferential maternal transmission, such as fragile X syndrome,132 Friedreich ataxia,133
spinocerebellar ataxia type 863 and myotonic dystrophy.134 Trinucleotide expansions may
also be involved in some cases of frontotemporal dementia, although results are not
conclusive.135,136 There is currently no evidence for trinucleotide repeat expansions in AD.
Maternal transmission in neurological disorders other than AD
A wide spectrum of diseases has been associated with preferential maternal transmission
resulting from various genetic mechanisms. Parkinson’s disease has more common features
with AD than the other disorders, and is therefore presented separately and in more detail.
Parkinson’s disease
Parkinsonian syndromes are movement disorders that can be divided into idiopathic
Parkinson’s disease (PD), multiple system atrophy (MSA) and parkinsonian syndromes
(PDS) secondary to other conditions or exogenous agents. While MSA and PDS are purely
movement disorders, it is not uncommon for PD patients to develop dementia.137 PD is a
neurodegenerative disease that typically impairs motor skills, speech and other cognitive
functions, and is characterised by muscle rigidity, tremor, bradykinesia (ie slowing of
physical movement) and akinesia (ie loss of physical movement) in severe cases.138 The
primary symptoms are the result of decreased stimulation of the motor cortex due to
degeneration of dopaminergic neurones in the substantia nigra.
As in AD, epidemiological data indicate that the risk of developing PD is greater for a
person whose mother was affected by the disease than for the off-spring of an affected
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father.139,140 Moreover, only maternal transmission of PD was found to affect the age at
onset in affected families.141
While there is no evidence for chromosome X mutations or imprinting in PD, it is now
widely accepted that inherited or somatic mtDNA variations contribute to the aetiology of
PD (Table 4). Mitochondrial damage in PD results in ETC complex I deficits (instead of the
ETC complex IV deficits typically observed in AD).95 PD was one of the first identified
neurodegenerative mitochondriopathies. In the early 1980s, a toxin-induced subacute
parkinsonism syndrome reminiscent of idiopathic PD was described.148 The responsible
toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), was next shown to inhibit
ETC complex I. MPTP administration to laboratory animals has been found to destroy the
substantia nigra and even induced Lewy body formation in aged chimpanzees.148
Subsequent research revealed that other complex I inhibitors induce a parkinsonism
phenotype, loss of dopaminergic nigral neurones and histological changes similar to those
seen in human PD.149 Complex I enzymatic lesions, but not other ETC enzymes, are found
in PD patients in both the substantia nigra and muscle,150 which may be due to mtDNA
mutations.151-153
The cybrid technique has provided an effective strategy for probing the role of mtDNA in
PD as well as AD subjects.154 To summarise the results of PD cybrid studies, transferring
PD platelet mitochondria to mtDNA-depleted human cells produced cell lines with reduced
complex I activity, elevated peroxide levels, increased antioxidant enzyme activities, altered
calcium and signalling pathway homeostasis and cytoplasmic protein aggregations that
contain α synuclein.155 Of great relevance to the imaging findings in children of AD
mothers, a cybrid study in PD examined ETC activity of multiple members over three
generations affected with PD through exclusively maternal lines and compared them with
those of paternally descended family members.156 Compared with the cybrid lines
containing mtDNA from paternal descendants, cybrid lines containing mtDNA from
maternal descendants had lower complex I activity, increased ROS production and more
abnormal mitochondrial morphologic features.156 These findings were present in cybrid
lines containing mtDNA from maternal descendants affected with PD as well as in
asymptomatic young maternal descendants.156 These data indicate that mtDNA mutations
may be a primary genetic deficit in maternally inherited PD. There are currently no
published imaging studies that have compared symptomatic or pre-symptomatic children of
PD mothers with children of PD fathers.
Maternal transmission of other neurological disorders—Several neurological
disorders show preferential maternal inheritance (Table 5). Overall, these maternally
inherited disorders are characterised by phenotypic manifestation mainly in infancy or early
adulthood. Disorders due to mtDNA mutations are more frequent and typically present as
multi-systemic diseases. None of these disorders resemble the clinical phenotype of AD;
however, some reports have suggested a link between AD and maternally inherited
neurological disorders. For example, mitochondrial haplogroup J has been associated with
increased risk of AD, MELAS and LHON.168
Conclusions, implications and future challenges
Clinical and epidemiological studies show that maternally inherited AD may account for
over 20 per cent of all LOAD cases, and children of AD mothers are at higher risk for
developing AD than children of AD fathers. Brain 18F-FDG PET studies have shown that
children of AD mothers are at risk of developing brain hypometabolism early in life, which
may partially explain the increased predisposition. Genetic mechanisms involved with
maternally inherited metabolic deficits in AD are under investigation.
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Metabolic deficits in normal individuals with a maternal history of AD represent a unique
opportunity for the initiation of AD therapies and general preventive methods years — and
possibly decades — prior to the onset of the clinical disease, presumably well before
significant neuronal loss occurs. CMRglc reductions in asymptomatic children of AD
mothers can ideally be used as a surrogate marker of AD progression in clinical trials to test
the potential of preventive treatments for AD.51 Moreover, they could be used as a
biomarker of AD in quantitative trait genetic analysis, instead of standard case-control
studies, to examine the genes involved in maternal transmission in AD. The combination of
imaging and custom-tailored genetics may help to clarify whether changes in the nuclear or
mitochondrial genome and transcriptome account for pathogenic ageing and AD.
It is important to underline that the genes involved in maternally inherited AD do not follow
an autosomal dominant pattern of transmission, and penetrance does not appear to be high,
as many children of mothers with AD do not develop the disease. Although the presence of a
maternal history of AD indicates that children may be at higher risk, it does not imply that
the children are carriers of the hypothesised mutated gene or allelic variant. The maternal
link may not be the only cause of AD in the children, who may develop sporadic AD, or AD
linked to non-maternal genetic risk factors for LOAD, however. All of these non-maternally
inherited genetic or sporadic causes of AD may also lead individuals to develop a metabolic
pattern comparable with that described in our studies. Moreover, the AD mothers may have
sporadic LOAD, which would probably not be inherited by the children. In this case, multi-
generational studies may help to identify individuals with a definite history of maternally
inherited AD spanning two or more generations.
Finally, evidence for early metabolic deficits in the children of AD mothers suggests that
this form of LOFAD may be both a neurodevelopmental and a neurodegenerative disorder.
Several studies have hypothesised a direct relationship between early development and late-
life neurodegeneration based on similarities between APP and the Notch protein, which is
critically involved in central and peripheral nervous system development and, like APP, is
cleaved by presenilins.169,170 APP was shown to be a ligand for death receptor 6 (DR6),
which triggers neurodegeneration during embryonal development.171 In particular, in NGF
knockout mice, trophic deprivation led to the cleavage of surface APP by beta-secretase,
with generation of an N-APP fragment which bound DR6, triggering caspase activation and
degeneration of both neuronal cell bodies (via caspase 3) and axons (via caspase 6).171
Therefore, the pathological process in AD may begin as early as at birth, as a result of lack
of trophic support and nutrients to the embryo. This observation suggests a role for
metabolic imprinting in neurodegeneration in AD, which can only be maternally inherited.
In conclusion, integration of information from genetic, transcriptomic and proteomic studies,
and from in vivo biomarkers, will greatly advance our understanding of the causes of AD,
improve our ability to establish an early diagnosis, help to define disease subgroups and,
ultimately, help to develop preventive treatments based on individuals’ own
pathophysiology.
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Figure 1.
Incidence of AD cases in the USA. State-specific projections up to 2025 (adapted from
Hebert et al.2).
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Figure 2.
Statistical parametric maps showing reduced brain glucose metabolism in cognitively
normal individuals with a maternal history of AD (FHm) compared with those with a
paternal history of AD (FHp, in red) and with those with no family history of AD (FH–, in
green).7 Brain regions showing hypometabolism in FHm compared with FHp and FH–
include the inferior parietal lobes, lateral and inferior temporal cortex, posterior cingulate/
precuneus and dorsolateral prefrontal cortex. These same brain regions are typically
hypometabolic in clinical AD patients. Figure shows the superior, posterior, right and left
lateral views of a three-dimensional volume-rendered MRI.
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Figure 3.
Statistical parametric maps showing CMRglc reductions over a two-year follow-up interval.
Compared with the baseline, reduced follow-up CMRglc was restricted to the frontal
cortices in normal subjects with no family history of AD (top row, in green) and in those
with an AD father (middle row, in blue), whereas follow-up CMRglc was reduced in inferior
parietal, lateral and inferior temporal, posterior cingulate/precuneus and prefrontal cortex in
normal individuals with a maternal history of AD (bottom row, in red). Figure shows the
anterior, right lateral, superior and mid-sagittal views of a three-dimensional volume-
rendered MRI.
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Figure 4.
18F-FDG PET scans of two cognitively normal (NL) individuals with postmortem-
confirmed AD parents. The 18F-FDG PET of the son of an AD father (left) shows no
CMRglc abnormalities, while the 18F-FDG PET of the daughter of an AD mother (right)
shows areas of reduced CMRglc (indicated by arrows).7 CMRglc measures are represented
on a colour-coded scale, ranging from 0 to 60 μmol glucose/100 g/min (right side of figure).
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Figure 5.
The cybrid technique (adapted from Kish et al.114). The procedure involves obtaining
mtDNA from persons with and without disease. Usually, platelets are used as the mtDNA
donor tissue, since platelets are easily obtained through standard phlebotomy, are easy to
isolate through centrifugation and lack nuclei. Mixing platelets with cell lines depleted of
their own endogenous mtDNA allows exchange of platelet and cell line materials, which
results in cell lines containing mtDNA from the individual platelet donors. These cell lines
expand under standard culture conditions, and their biochemical assessment allows
investigators to evaluate parameters directly or indirectly referable to mitochondria and the
mtDNA they carry. Differences in mtDNA lead to differences in the mtDNA-encoded
subunits of oxidative phosphorylation complexes I, III, IV and V. Functional differences
between cybrid cell lines should reflect differences in mtDNA that cause changes in these
enzyme complexes.
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Table 3
Mitochondrial DNA mutations and haplotypes associated with late-onset AD
Approach Finding Positive findings Negative
findings
Case-control
mutation
identification
T146G,
T195C,
T152C,
A189G,
T414G
Increased AD
risk121
No mutation
found122
4977 bp
deletion
More frequent in
AD patients123
A4336G More frequent in
AD patients124,125
No
association
with AD126
Haplogroup
association
K, U Decreased risk of
AD, neutralising
the effect of ApoE
genotype127
No effect of
K
haplogroup
in AD128
U Increased risk in
males, decreased
risk in females128
J Increased in AD
patients in a
French-Canadian
population129
No AD
haplogroup
association
in US
population122
T Decreased AD risk
in a French-
Canadian
population129
No AD
haplogroup
association
in US
population122
bp = base pair
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Table 4
Mitochondrial DNA mutations and haplotypes associated with Parkinson’s disease (PD)
mtDNA
haplogroup or
mutation
Hypothesised
role
Reference
Haplogroup J, K Lower PD risk Van der Walt et al.142
UKJT haplogroup
supercluster
Lower PD risk Pyle et al.143
JTIWX
haplogroup
supercluster
Higher PD and
PD with
dementia risk
Autere et al.144
Haplogroup I, J, K Decreased risk
for PD but
increased risk
for PD with
dementia
Autere et al.144
mtDNA
mutation:
10398G (J, K, I
haplogroups)
Lower PD risk Van der Walt et al.;142
Autere et al.144
mtDNA
mutation: 9055A
Lower PD risk
(only in women)
Van der Walt et al.142
mtDNA
mutation: 4216C
(ND1 gene)
Increased PD
risk
Kirchner et al.145
mtDNA
mutation: 4216C
(ND1 gene)
No difference
observed
Huerta et al.146
mtDNA
mutation: 4336
(tRNAglu)
More frequent in
PD patients
Tan et al.147
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